Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea
- PMID: 9264286
- DOI: 10.1089/aid.1997.13.995
Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea
Abstract
Four sera from Equatorial Guinea (EG) suspected to contain antibody against HIV-1 group O-related viruses were identified on the basis of unusual and differential serologic reactivity in selected commercial assays and Western blot. Degenerate primers, designed from HIV-1 group O published sequences, were used to PCR amplify envelope (env) gene sequences from the suspect EG sera. A complete envelope gene sequence from each serum was determined from the overlapping env gene fragments. Analysis (PHYLIP package of programs) of Env amino acid sequences (translated from nucleotide sequences) indicated that the amino acid sequences obtained from EG sera clustered more closely with HIV Env sequences of group O compared to group M. The amino acid sequences at the octameric tip of the V3 loop were either RIGPLAWY (one isolate), RIGPMAWY (two isolates), or GLGPLAVY (one isolate). The V3 tip tetrameric sequence GPLA is represented only once in the 1995 HIV (Los Alamos) database, but was present in two of our group O-related EG samples. The gp41 immunodominant regions (IDR) protein sequences were identical for sequences from three of the sera, RLLALETLIQNQQLLNLWGCKGR(K)L(I)VCYTSVK(T)W, whereas sequence from the fourth serum contained three changes as noted in parentheses. IDR sequences derived from EG sera were unique compared to those reported for other HIV-1 group O isolate ANT70, VAU, or MVP5180. Antibody in each EG serum directed against the IDR could be detected using synthetic peptides comprising sequences from the ANT70 or MVP5180 IDRs, but were most reactive against the sequences derived from the samples themselves. Little or no serologic reactivity was detected when EG sera were reacted against peptides comprising the IDR of HIV-1 group M (subtype B consensus) or HIV-2 (consensus).
PIP: The genetic variation and epidemiology of HIV-1 group O isolates are of considerable importance to the design of HIV-1 diagnostic and screening assays, especially since current serologic and genetic methods to detect HIV-1 have been developed mainly on the basis of sequences from isolates belonging to HIV-1 group M. The HIV envelope protein, especially the gp41 immunodominant region, plays a major antigenic role in the detection of HIV infection and for discriminating HIV-1 from HIV-2 antibody. This paper reports upon genetic variation and the serologic characterization of env sequences from 4 people living in Equatorial Guinea (EG) who were infected with HIV-1 group O. Selected commercial assays and Western blot were first used to identify the sera, then degenerate primers, designed from HIV-1 group O published sequences, were used to PCR amplify envelope (env) gene sequences. A complete envelope gene sequence from each serum was determined from the overlapping env gene fragments. The env amino acid sequence analysis found the EG sera sequences to be clustered more closely with the HIV env sequences of group O rather than to group M. The amino acid sequences at the octameric tip of the V3 loop were either RIGPLAWY, RIGPMAWY, or GLGPLAVY. Although the V3 tip tetrameric sequence GPLA is represented only once in the 1995 HIV database, it was present in 2 of the group O-related EG samples. The gp41 immunodominant regions (IDR) protein sequences were identical for sequences from 3 of the sera. IDR sequences derived from the EG sera were unique compared to those reported for other HIV-1 group O isolates ANT70, VAU, or MVP5180. Other findings are discussed in detail.
Similar articles
-
Molecular analyses of HIV-1 group O and HIV-2 variants from Africa.Leukemia. 1997 Apr;11 Suppl 3:138-41. Leukemia. 1997. PMID: 9209322
-
A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.AIDS. 1993 Jun;7(6):759-67. doi: 10.1097/00002030-199306000-00002. AIDS. 1993. PMID: 8363754
-
Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.AIDS Res Hum Retroviruses. 1994 Nov;10(11):1551-6. doi: 10.1089/aid.1994.10.1551. AIDS Res Hum Retroviruses. 1994. PMID: 7534097
-
Antigenic and immunogenic sites of HIV-2 glycoproteins.Chem Immunol. 1993;56:61-77. doi: 10.1159/000319156. Chem Immunol. 1993. PMID: 8452654 Review.
-
Roles of HIV-1 Env variable regions in viral neutralization and vaccine development.Curr HIV Res. 2007 Nov;5(6):542-53. doi: 10.2174/157016207782418470. Curr HIV Res. 2007. PMID: 18045110 Review.
Cited by
-
Detection of phylogenetically diverse human immunodeficiency virus type 1 groups M and O from plasma by using highly sensitive and specific generic primers.J Clin Microbiol. 1999 Aug;37(8):2581-6. doi: 10.1128/JCM.37.8.2581-2586.1999. J Clin Microbiol. 1999. PMID: 10405405 Free PMC article.
-
Significant genetic and antigenic variability within the env gene of systemic human immunodeficiency virus type 1 group O populations during the natural course of a heterosexual infection: a pilot study.J Clin Microbiol. 2007 Apr;45(4):1319-21. doi: 10.1128/JCM.01818-06. Epub 2007 Jan 31. J Clin Microbiol. 2007. PMID: 17267630 Free PMC article.
-
Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2.J Clin Microbiol. 1998 Dec;36(12):3657-61. doi: 10.1128/JCM.36.12.3657-3661.1998. J Clin Microbiol. 1998. PMID: 9817891 Free PMC article.
-
Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.J Virol. 1998 Nov;72(11):9002-15. doi: 10.1128/JVI.72.11.9002-9015.1998. J Virol. 1998. PMID: 9765445 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases